当前位置:首页>产品中心>单抗/多抗>Anti-Human CD272/BTLA Reference Antibody|抗人CD272/BTLA参照抗体(靶标:人B和T淋巴细胞衰减因子/CD272(研究用))

Anti-Human CD272/BTLA Reference Antibody|抗人CD272/BTLA参照抗体(靶标:人B和T淋巴细胞衰减因子/CD272(研究用))

  • 货号:RB9THV375076
  • 价格:面议
  • 点击:385
   一键复制产品信息 复制成功!

产品介绍

产品参数

形态Liquid
宿主种属Human
克隆性Monoclonal
抗体亚型IgG4, kappa
纯度>95% as determined by SDS-PAGE.
纯化方式Protein A/G purified from cell culture supernatant.
内毒素水平< 10 EU/mg
应用ELISA, Bioactivity: FACS, Functional assay, Research in vivo
种属反应性Human
储存缓冲液0.01 M PBS pH 7.4
稳定性和储存Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -120°C long term.
产品使用说明ELISA: 1:2000-1:20000
登录号Q7Z6A9
背景信息

B- and T-lymphocyte attenuator (CD272/BTLA) is a ~32 kDa protein. Inhibitory receptor on lymphocytes that negatively regulates antigen receptor signaling via PTPN6/SHP-1 and PTPN11/SHP-2. May interact in cis (on the same cell) or in trans (on other cells) with TNFRSF14. In cis interactions, appears to play an immune regulatory role inhibiting in trans interactions in naive T cells to maintain a resting state. In trans interactions, can predominate during adaptive immune response to provide survival signals to effector T cells.

1. Watanabe, N. et al. (2003) Nature immunology 4, 670-9. PMID: 12796776
2. Gavrieli, M. et al. (2003) Biochemical and biophysical research communications 312, 1236-43. PMID: 14652006
3. Sedy, JR. et al. (2005) Nature immunology 6, 90-8. PMID: 15568026
4. Cai, G. et al. (2008) Nature immunology 9, 176-85. PMID: 18193050
5. Cheung, TC. et al. (2009) Journal of immunology (Baltimore, Md. : 1950) 183, 7286-96. PMID: 19915044
备注For research use only.
【仅供科学研究使用】

相关产品:
产品名称 点击数
Anti-Daclizumab Neutralizing Recombinant Antibody |抗达克珠单抗中和重组抗体(靶标:达克珠单抗中和抗体) 582
Anti-Daclizumab Neutralizing Recombinant Antibody |抗达克珠单抗中和重组抗体(靶标:达克珠单抗中和抗体) 773
Anti-Daclizumab Neutralizing Recombinant Antibody |抗达克珠单抗中和重组抗体(靶标:达克珠单抗中和抗体) 540
Anti-Daclizumab Neutralizing Recombinant Antibody |抗达克珠单抗中和重组抗体(靶标:达克珠单抗中和抗体) 711
Anti-Atibuclimab Neutralizing Recombinant Antibody |抗阿替布利单抗中和重组抗体(靶标:阿替布利单抗中和抗体) 565
Anti-Atibuclimab Neutralizing Recombinant Antibody |抗阿替布利单抗中和重组抗体(靶标:阿替布利单抗中和抗体) 642
Anti-Atibuclimab Neutralizing Recombinant Antibody |抗阿替布利单抗中和重组抗体(靶标:阿替布利单抗中和抗体) 400
Anti-Atibuclimab Neutralizing Recombinant Antibody |抗阿替布利单抗中和重组抗体(靶标:阿替布利单抗中和抗体) 472
Anti-Secukinumab Neutralizing Recombinant Antibody |抗司库奇尤单抗中和重组抗体(靶标:司库奇尤单抗中和抗体) 489
Anti-Secukinumab Neutralizing Recombinant Antibody |抗司库奇尤单抗中和重组抗体(靶标:司库奇尤单抗中和抗体) 664
Anti-Secukinumab Neutralizing Recombinant Antibody |抗司库奇尤单抗中和重组抗体(靶标:司库奇尤单抗中和抗体) 782
Anti-Secukinumab Neutralizing Recombinant Antibody |抗司库奇尤单抗中和重组抗体(靶标:司库奇尤单抗中和抗体) 592
Anti-Enfortumab Neutralizing Recombinant Antibody |抗恩福妥单抗中和重组抗体(靶标:恩福妥单抗中和抗体) 521
Anti-Enfortumab Neutralizing Recombinant Antibody |抗恩福妥单抗中和重组抗体(靶标:恩福妥单抗中和抗体) 749
Anti-Enfortumab Neutralizing Recombinant Antibody |抗恩福妥单抗中和重组抗体(靶标:恩福妥单抗中和抗体) 803
Anti-Enfortumab Neutralizing Recombinant Antibody |抗恩福妥单抗中和重组抗体(靶标:恩福妥单抗中和抗体) 623
Anti-Certolizumab Non-Neutralizing Recombinant Antibody |抗赛妥珠单抗非中和重组抗体(靶标:赛妥珠单抗非中和抗体) 514
Anti-Certolizumab Non-Neutralizing Recombinant Antibody |抗赛妥珠单抗非中和重组抗体(靶标:赛妥珠单抗非中和抗体) 768
Anti-Certolizumab Non-Neutralizing Recombinant Antibody |抗赛妥珠单抗非中和重组抗体(靶标:赛妥珠单抗非中和抗体) 652
Anti-Certolizumab Neutralizing Recombinant Antibody |抗赛妥珠单抗中和重组抗体(靶标:赛妥珠单抗中和抗体) 477
总计 33037 个记录,共 1652 页,当前第 1650 页 | 第一页 上一页 下一页 最末页
在线客服
  • 销售热线:
  • 15898894496(同微信)
  • 我要留言
  • 周一至周五每天9:00-17:00